Acthib, Omnihib Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high burden of hib related infections, proven vaccine effectiveness, global childhood immunization initiatives, public health funding support, early inclusion in vaccination schedules.

The growth in the forecast period can be attributed to continued focus on infant immunization coverage, expansion in emerging economies, government supported vaccination campaigns, improved vaccine access logistics, rising awareness of bacterial meningitis prevention. Major trends in the forecast period include sustained demand for routine pediatric immunization, rising adoption of combination childhood vaccines, expansion of national immunization programs, improved vaccine cold chain infrastructure, growing focus on preventable bacterial infections.

The rising prevalence of Haemophilus influenzae type b (Hib) infections is expected to drive the growth of the acthib, omnihib market in the coming years. Hib infections are serious bacterial illnesses caused by Haemophilus influenzae type b, leading to conditions such as meningitis, pneumonia, and epiglottitis, and primarily affecting young children. The increase in Hib infections is largely attributed to declining vaccination rates, as reduced immunization coverage weakens herd immunity and increases vulnerability to infection. ActHIB and OmniHIB are used to prevent Hib infections by stimulating the immune system to recognize and combat Haemophilus influenzae type b bacteria. For example, in October 2025, according to the Australian Institute of Health and Welfare, an independent statutory government agency, 94% of Australian one-year-olds and 93% of two-year-olds were fully vaccinated against Hib in 2023. Therefore, the increasing prevalence of Haemophilus influenzae type b infections is supporting growth in the acthib, omnihib market.

The expansion of research and development activities is also expected to propel the growth of the acthib, omnihib market. Research and development activities involve the systematic investigation and creation of new knowledge, products, or technologies through scientific research and experimentation. The increase in R&D efforts is driven by rising demand for safer and more effective therapies that improve patient outcomes and enhance treatment precision. These activities strengthen the ActHIB and OmniHIB market by improving vaccine formulations, enhancing immunogenicity, and increasing production efficiency. They support optimization of conjugation technologies, extension of vaccine stability, and development of combination vaccine options, ultimately improving protection against Hib infections and expanding access through global immunization programs. For instance, in July 2025, Eurostat reported that total government budget allocations for R&D across the European Union reached approximately €127.91 billion in 2024, representing a 3.4% increase from €123.67 billion in 2023. As a result, increasing research and development activities are driving growth in the acthib, omnihib market.

Rising healthcare expenditure is also expected to contribute to the growth of the acthib, omnihib market. Healthcare expenditure includes total spending on medical services, hospital care, medications, and public health initiatives by governments, organizations, and individuals. The growing demand for healthcare spending is driven by the increasing prevalence of chronic diseases that require long-term and costly treatment. Higher healthcare expenditure supports the ActHIB and OmniHIB market by expanding access to routine immunizations and strengthening national vaccination programs. It enables greater investment in pediatric preventive care, allowing healthcare systems and governments to increase Hib vaccine coverage and improve supply availability. For example, in May 2024, the UK Office for National Statistics reported that total healthcare expenditure rose by 5.6% in nominal terms in 2023, compared with 0.9% growth in 2022. Therefore, rising healthcare expenditure is fueling the growth of the acthib, omnihib market.

Major companies operating in the acthib, omnihib market are Sanofi SA.

North America was the largest region in the acthib, omnihib market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acthib, omnihib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acthib, omnihib market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately affected the acthib omnibhib market by increasing costs related to vaccine raw materials and sterile manufacturing components. These impacts are most visible in public immunization supply chains across asia pacific and africa. Higher tariffs can influence procurement costs for government vaccination programs. However, tariffs are also supporting localized vaccine production and regional manufacturing capacity. This strengthens long term vaccine supply security.

The acthib, omnihib market research report is one of a series of new reports that provides acthib, omnihib market statistics, including acthib, omnihib industry global market size, regional shares, competitors with a acthib, omnihib market share, detailed acthib, omnihib market segments, market trends and opportunities, and any further data you may need to thrive in the acthib, omnihib industry. This acthib, omnihib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

ActHIB and omnihib are vaccines used to prevent invasive diseases caused by Haemophilus influenzae type b (Hib), such as meningitis and pneumonia. ActHIB is a conjugate vaccine containing the Hib capsular polysaccharide linked to a protein, while OmniHIB is a similar conjugate vaccine. Both are typically administered to infants and children to provide immunity and play a key role in reducing severe or potentially fatal Hib-related illnesses.

The main vaccine types of acthib, omnihib are monovalent Hib vaccines and combination vaccines. Monovalent Hib vaccines are designed to protect specifically against Haemophilus influenzae type b infections. These vaccines contain a component of the Hib bacterium that helps the immune system recognize and combat the infection. Clinical indications include Haemophilus influenzae type b (Hib) infection. They are used in age groups including infants, toddlers, and adults, with end users such as hospitals, clinics, and retail pharmacies.

The acthib, omnihib market consists of sales of Hib vaccines, boosters, and pediatric vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.